Brain News and Research

RSS

The human brain is the center of the human nervous system and is a highly complex organ. Enclosed in the cranium, it has the same general structure as the brains of other mammals, but is over three times as large as the brain of a typical mammal with an equivalent body size.

Biogen, Elan announce clinical utility data of two-step ELISA to detect anti-JCV antibodies

Biogen Idec and Elan Corporation, plc today announced data further supporting the potential clinical utility of an investigational assay that detects anti-JC virus (JCV) antibodies in human plasma or serum.

18 Oct 2010

Genetic link to depression: New avenues for therapy

Yale University scientists have found a gene that appears to play a key role in the onset of depression. This could mean new avenues of therapy for the disease. The gene in question is called MKP-1 and was identified after comparing the genetic codes of 21 deceased people who had been diagnosed with depression with those of 18 otherwise healthy individuals. The findings were published in the journal Nature Medicine on 17th of October.

18 Oct 2010

ASA to salute U.S. military members at 2010 Annual Meeting

The American Society of Anesthesiologists (ASA) will salute its military members as well as all U.S. service members and their families during the Society's 2010 Annual Meeting in San Diego, CA, October 16 - 20.

18 Oct 2010

Nektar presents NKTR-181 preclinical data at ASA 2010 Annual Meeting

Nektar Therapeutics today presented new preclinical data demonstrating that NKTR-181, a mu-opioid analgesic with a novel molecular structure, dramatically reduces abuse liability while providing analgesia comparable to oxycodone and morphine.

18 Oct 2010

Teva Pharmaceutical announces new data from PreCISe study

Teva Pharmaceutical Industries Ltd. today announced new data from the five-year extension of the PreCISe study demonstrating that earlier initiation of treatment with Copaxone (glatiramer acetate injection) in patients presenting with first signs of multiple sclerosis (MS), provided greater effects in delaying conversion to clinically definite MS (CDMS) compared to later treatment initiation after diagnosis of CDMS or after three years on the study.

18 Oct 2010

Neuroprotective properties of laquinimod for RRMS presented at 26th ECTRIMS Congress

Teva Pharmaceutical Industries Ltd. and Active Biotech announced today that data providing further evidence of the neuroprotective properties of laquinimod in animal studies were presented at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Gothenburg, Sweden.

15 Oct 2010

Genentech and Biogen Idec announce positive results from ocrelizumab phase II RRMS study

Genentech, Inc., a member of the Roche Group, and Biogen Idec today announced 24-week results from a phase II study of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS), the most common form of the disease. Ocrelizumab demonstrated a significant reduction in disease activity as measured by brain lesions and relapse rate.

15 Oct 2010

Few Americans plan for Alzheimer's despite rise in awareness

A growing number of Americans report knowing a relative or friend afflicted with Alzheimer's, according to a national poll conducted by the public opinion research firm Abt SRBI. Yet despite this rise in awareness, often accompanied by significant anxiety about one day getting this fatal brain disease, few Americans are planning for its eventuality.

15 Oct 2010

Pericytes regulate blood-brain barrier

While the blood-brain barrier (BBB) protects the brain from harmful chemicals occurring naturally in the blood, it also obstructs the transport of drugs to the brain. In an article in Nature scientists at the Swedish medical university Karolinska Institutet now present a potential solution to the problem. The key to the BBB is a cell-type in the blood vessel walls called pericytes, and the researchers hope that their findings will one day contribute to new therapies for diseases like Alzheimer's and stroke.

15 Oct 2010

Bristol-Myers, Otsuka launch My SPRYCEL Support program to assist patients with CML

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced the launch of My SPRYCEL (dasatinib) Support, a useful resource to assist adult patients with chronic myeloid leukemia (CML) who are taking SPRYCEL.

15 Oct 2010

Acorda presents new analysis of AMPYRA tablets at ECTRIMS Congress

Acorda Therapeutics, Inc. today announced that a new analysis of AMPYRA (dalfampridine) Extended Release Tablets, 10 mg data examining walking improvement in treatment responders has been presented at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

15 Oct 2010

Fluctuations in internal body temperature regulate body's circadian rhythm: Research

Researchers at UT Southwestern Medical Center have found that fluctuations in internal body temperature regulate the body's circadian rhythm, the 24-hour cycle that controls metabolism, sleep and other bodily functions.

15 Oct 2010

Emerging Healthcare anticipates results of FDA-approved human embryonic stem-cell treatment

Emerging Healthcare Solutions, Inc. eagerly anticipates the results of the first FDA-approved human embryonic stem-cell treatment on a patient with spinal cord injuries, which began this week.

15 Oct 2010

Questcor, CNF partner to fund infantile spasms research

Questcor Pharmaceuticals, Inc. announced that it is partnering with the Child Neurology Foundation (CNF) to fund a $30,000 grant to support research into infantile spasms (IS). Catherine Chu-Shore, MD, of Massachusetts General Hospital was selected by CNF as the recipient of this first-ever "Logan Infantile Spasms Research Award."

15 Oct 2010

MedSolutions, Corporate Research Group announce initial results from diagnostic accuracy program

MedSolutions and Corporate Research Group today announced initial results from a groundbreaking diagnostic accuracy program, which showed shortened hospital stays, reduced emergency room visits and lower overall medical costs among participants.

15 Oct 2010

UCLA study sheds light on roots of schizophrenia, autism

UCLA scientists have discovered that exposing fetal neurons to higher than normal levels of a common immune protein leads to abnormal brain development in mice.

15 Oct 2010

Sanofi-aventis announces TEMSO phase III study results for relapsing multiple sclerosis

Sanofi-aventis announced today the results from the two year phase III TEMSO study of teriflunomide, a novel oral disease modifier investigated for the treatment of relapsing multiple sclerosis (RMS).

15 Oct 2010

MRI-guided laser ablation offers way to kill tumors

Physicians at Mayo Clinic's Florida campus are among the first in the nation to use a technique known as MRI-guided laser ablation to heat up and destroy kidney and liver tumors. So far, five patients have been successfully treated meaning no visible tumors remained after the procedure.

15 Oct 2010

Genzyme reports five-year patient data from Phase 2 multiple sclerosis trial

Genzyme Corporation today reported five-year patient data from its completed Phase 2 multiple sclerosis (MS) trial. This sub-group analysis found that nearly 90 percent of alemtuzumab-treated patients were free of sustained accumulation of disability, and that patients receiving alemtuzumab also maintained improved mean disability scores and a low risk of relapse over the 60-month follow-up period.

15 Oct 2010

Lantheus announces Canadian launch of ABLAVAR injection

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced the Canadian launch of ABLAVAR (gadofosveset trisodium injection), a unique, injectable magnetic resonance angiography (MRA) blood pool imaging agent.

15 Oct 2010

Brain News and Research

Further Reading

Biogen, Elan announce clinical utility data of two-step ELISA to detect anti-JCV antibodies

Genetic link to depression: New avenues for therapy

ASA to salute U.S. military members at 2010 Annual Meeting

Nektar presents NKTR-181 preclinical data at ASA 2010 Annual Meeting

Teva Pharmaceutical announces new data from PreCISe study

Neuroprotective properties of laquinimod for RRMS presented at 26th ECTRIMS Congress

Genentech and Biogen Idec announce positive results from ocrelizumab phase II RRMS study

Few Americans plan for Alzheimer's despite rise in awareness

Pericytes regulate blood-brain barrier

Bristol-Myers, Otsuka launch My SPRYCEL Support program to assist patients with CML

Acorda presents new analysis of AMPYRA tablets at ECTRIMS Congress

Fluctuations in internal body temperature regulate body's circadian rhythm: Research

Emerging Healthcare anticipates results of FDA-approved human embryonic stem-cell treatment

Questcor, CNF partner to fund infantile spasms research

MedSolutions, Corporate Research Group announce initial results from diagnostic accuracy program

UCLA study sheds light on roots of schizophrenia, autism

Sanofi-aventis announces TEMSO phase III study results for relapsing multiple sclerosis

MRI-guided laser ablation offers way to kill tumors

Genzyme reports five-year patient data from Phase 2 multiple sclerosis trial

Lantheus announces Canadian launch of ABLAVAR injection

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News